AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC. The FDA granted priority review for Datroway based on results from the TROPION-Breast02 Phase III trial. The trial reported a 43% reduction in disease progression or death and an ORR of 64% versus 30% chemotherapy. Credit: 89stocker/Shutterstock.com. AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab deruxtecan) to treat metastatic triple-negative breast cancer (TNBC). The approval allows Datroway to be used as a first-line treatment for adults with unresectable or metastatic TNBC…

Source: Pharmaceutical Technology